Long-term intervention with heparins in a rat model of peritoneal dialysis

Peritoneal Dialysis International

Volumn 29, Issue 1, 2009, Pages 26-35

  Schilte, Margot N ^a   Loureiro, Jesus ^a,b   Keuming, Eelco D ^a   ter Wee, Piet M ^a   Celie, Johanna W A M ^a   Beelen, Robert H J ^a   van den Born, Jacob ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Epithelial to mesenchymal transition; Fibrosis; Heparin; Mesothelium; Morphology; Peritoneal transport

Indexed keywords

CD31 ANTIGEN; CYTOKERATIN; HEPARIN; HYALURONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PERITONEAL DIALYSIS FLUID; VIMENTIN; ANTICOAGULANT AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; ARTICLE; CELL DENSITY; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; DIALYSATE LEVEL; DRUG EFFICACY; EOSINOPHIL; EXTRACELLULAR MATRIX; GLUCOSE ABSORPTION; LONG TERM CARE; MAST CELL; MEMBRANE STRUCTURE; MESENTERY; MESOTHELIUM CELL; NEUTROPHIL; NONHUMAN; OMENTUM; PERITONEAL DIALYSIS; PERITONEUM; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; SPINDLE CELL; ULTRAFILTRATION; UREA CYCLE; WISTAR RAT; ANIMAL; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FIBROSIS; FOLLOW UP; MALE; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TIME; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTICOAGULANTS; BIOLOGICAL TRANSPORT; DISEASE MODELS, ANIMAL; FIBROSIS; FOLLOW-UP STUDIES; HEPARIN; KIDNEY FAILURE, CHRONIC; MALE; MESENTERY; NEOVASCULARIZATION, PATHOLOGIC; OMENTUM; PERITONEAL DIALYSIS; PERITONEUM; RATS; RATS, WISTAR; TIME FACTORS;

EID: 65349151892     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900105     Document Type: Article

References (41)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of pitients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
2. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55:341-56.
3. Davies SJ, Phillips L, Naish PF, RusseLL GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
4. Oh KH, Margetts PJ. Cytokines and growth factors involved in peritoneal fibrosis of peritoneal dialysis patients. Int J Artif Organs 2005; 28:129-34.
5. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymaltransition of mesothelial cells. N Engl J Med 2003; 348:403-13.
6. Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 2001; 57:159-206.
7. Tangelder GJ, Arfors KE. Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood 1991; 77:1565-71.
8. Nelson RM, Cecconi 0, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253-8.
9. Xie X, Thorlacius H, Raud J, Hedqvist P, Lindbom L. Inibitory effect of locally administered heparin on leukocyte rolling and chemoattractant-induced firm adhesion in rat mesenteric venules in vivo. Br J Pharmacol 1997; 122:906-10.
10. Bounameaux H. Unfractionated versus Low-molecularweight heparin in the treatment of venous thromboembolism. Vasc Med 1998; 3:41-6.
11. Sandercock P, CounseLL C, Stobbs SL. Low-molecularweight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke. Cochrane Database Syst Rev 2005; (2):CDO00119.
12. De Vriese AS, Mortier S, Cornelissen M, Patmans E, Vanacker NJ, Leyssens A, et al. The effects of heparin administration in an animal model of chronic peritoneal dialysate exposure. Perit Dial Int 2002; 22:566-72.
13. Pawlaczyk K, KuzLan-PawLaczyk M, Anderstam B, Heimburger O, Bergstrom J, Waniewski J, et al. Effects of intraperitoneal heparin on peritoneal transport in a chronic animal model of peritoneal dialysis. Nephrol Dial Transplant 2001; 16:669-71.
14. SjoLand JA, Smith PR, Jespersen J, Gram J. Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients. Nephrol Dial Transplant 2004; 19:1264-8.
15. Bazargani F, Albrektsson A, Yahyapour N, Braide M. Low molecularweight heparin improves peritonealultrafiltration and blocks complement and coagulation. Perit Dial Int 2005; 25:394-404.
16. Ponce SP, Barata JD, Santos JR. Interference of heparin with peritoneal solute transport. Nephron 1985; 39:47-9.
17. Beeten RH, Hekking LH, Zareie M, van den Born J. Rat models in peritoneal dialysis. Nephrol Dial Transplant 2001; 16:672-4.
18. Hekking LH, Zareie M, Driesprong BA, Faict D, Welten AG, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense in rats after Long-term exposure to a bicarbonate/ lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
19. Hekking LHP, Aalders MC, Van Gelderop E, Zweers MM, Struijk DG, Havenith CE, et al. Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis. Adv Perit Dial 1998; 14:14-18.
20. Zareie M, De Vriese AS, Hekking LH, ter Wee PM, Schalkwijk CG, Driesprong BA, et al. Immunopathological changes in a uraemic rat model for peritoneal dialysis. Nephrol Dial Transplant 2005; 20:1350-61.
21. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microcirculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20:2783-92.
22. Zareie M, van Lambalgen AA, ter Wee PM, Hekking LH, Keuning ED, Schadee-Eestermans IL, et al. Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int 2005; 25: 58-67.
23. Zareie M, Fabbrini P, Hekking LH, Keuning ED, ter Wee PM, Beelen RH, et al. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. J Am Soc Nephrol 2006; 17:3447-57.
24. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005; 29:638-50.
25. Fosang AJ, Hey NJ, Carney SL, Hardingham TE. An ELISA plate-based assay for hyaluronan using biotinylated proteoglycan G1 domain (HA-binding region). Matrix 1990; 10:306-13.
26. Whitaker D, Papadimitriou JM, Walters MN. The mesothelium; techniques for investigating the origin, nature and behaviour of mesothelial cells. J Pathol 1980; 132:263-71.
27. Norrby K. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis. Int J Exp Pathol 2000; 81:191-8.
28. Gunerhan Y, Koksal N, Gul O, Uzun MA, Gunes P, Adaleti R. Effects of unfractionated heparin and low-molecular-weight heparin on colonic anastomoses in the presence of experimental peritonitis. Eur Surg Res 2006; 38:353-7.
29. Arikan S, Adas G, Barut G, Toklu AS, Kocakusak A, Uzun H, et al. An evaluation of low molecular weight heparin and hyperbaric oxygen treatment in the prevention of intra-abdominal adhesions and wound healing. Am J Surg 2005; 189:155-60.
30. Kaplan GG, Manns B, McLaughlin K. Heparin induced thrombocytopaenia secondary to intraperitoneal heparin exposure. Nephrol Dial Transplant 2005; 20:2561-2.
31. Demirkan F, Akarsu M, Sifil A, Tutucu KN. Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients. Nephron 2002; 91:162-3.
32. Sifil A, Mermut C, Yenicerioglu Y, Cavdar C, Gumustekin M, Celik A, et al. Intraperitoneal and subcutaneous pharmacokinetics of low molecular weight heparin in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19:28-30.
33. Rosengren BI, Carlsson O, Rippe B. Hyaluronan and peritoneal ultrafiltration: a test of the "filter-cake" hypothesis. Am J Kidney Dis 2001; 37:1277-85.
34. Rippe B, Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three-pore membrane/fiber matrix model. Am J Physiol Renal Physiol 2007; 292: F1035-F1043.
35. Wan JG, Mu JS, Zhu HS, Geng JG. N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002; 51:435-43.
36. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110:127-36.
37. Gao Y, Li N, Fei R, Chen Z, Zheng S, Zeng X. P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol Cells 2005; 19: 350-5.
38. Borsig L, Wang L, Cavalcante MC, Cardilo-Reis L, Ferreira PL, Mourao PA, et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 2007; 282:14984-91.
39. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114:79-102.
40. Fernandez PM, Patierno SR, Rickles FR. Tissue factor and fibrin in tumor angiogenesis. Semin Thromb Hemost 2004; 30:31-44.
41. Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007; 102:840-7.